Please select the option that best describes you:
What dose-fractionation do you use when treating primary NSCLC with oligometastatic disease?
We've seen quite a few patients present with NSCLC with a single brain metastasis and a good performance status. Would you advocate for an aggressive definitive dose-fractionation approach e.g. 60-66Gy with concurrent chemotherapy and or a traditional palliative fractionation? Somewhere in between?
Answer from: Radiation Oncologist at Academic Institution
The approach to the lung primary in a patient with a single brain metastasis is dependent in our experience on clearly defining the extent of disease in the chest. Thus, the unusual presentation of a single brain lesion with an isolated primary (i.e.,. no regional nodal or distant disease) in the ch...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
There are a couple of series that suggest that for patients with oligometastatic disease with Stage III disease in the chest, that these patients can achieve significant long-term survival outcomes with definitive thoracic chemoRT (for example Khan A et al and Jabbour SK et al). Our approach is to ...